Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERTseverance: PERT for PEI in Unresectable Pancreatic Cancer
NCT06099119Phase 4Recruiting
- Sponsor
- Complejo Hospitalario Universitario de Santiago
- Start
- Feb 2024
- Primary completion
- Jun 2027
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 4 trial of pancreatin in pancreatic exocrine insufficiency (EPI), sponsored by Complejo Hospitalario Universitario de Santiago. Started Feb 2024; status: recruiting.
02
Drugs
pancreatin
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT06099119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099119.